Non–Small Cell Lung Cancer, Version 4.2024Gregory J. Riely, Lisa Hang, Thomas J. Dilling et al.|Journal of the National Comprehensive Cancer Network|2024Cited by 746
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLCMarcelo V. Negrão, Sandip Pravin Patel, Haniel A. Araújo et al.|Cancer Discovery|2023Cited by 181
Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) ConsortiumTalal El Zarif, Danai Dima, Amin H. Nassar et al.|Journal of Clinical Oncology|2023Cited by 69
Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic CarcinomaDwight H. Owen, Gregory A. Otterson|Journal of Thoracic Oncology|2018Cited by 61
Novel STK11 differentiation phenotype classifier STK11-DPC: Immunosuppressive tumor microenvironment (TME) and response to immune checkpoint blockade (ICB) in STK11-deficient NSCLC.Jacob Kaufman, David P. Carbone, Dwight H. Owen et al.|Journal of Clinical Oncology|2023Cited by 1